IWWM-11 2022 | Long-term follow-up on the efficacy of BTK inhibitors in WM
Constantine Tam
• 29 Oct 2022
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Alfred Health, Monash University, Melbourne, Australia, briefly discusses long-term follow-up data on Bruton’s tyrosine kinase (BTK) inhibitors in Waldenström’s macroglobulinemia (WM), highlighting the efficacy of these agents, as well as the long-term progression-free survival (PFS) observed in patients. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
